Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2014 17:02 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed to Present Data From Three Clinical Studies at the 2014 ASCO Annual Meeting

REDWOOD CITY, Calif., May 14, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
May 08, 2014 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals Announces First Quarter 2014 Financial Results

REDWOOD CITY, Calif., May 8, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
May 02, 2014 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Receives Orphan Drug Designation From the FDA for Demcizumab in Pancreatic Cancer

REDWOOD CITY, Calif., May 2, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
April 23, 2014 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Announces Abstracts Accepted at the 2014 ASCO Annual Meeting

REDWOOD CITY, Calif., April 23, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
April 08, 2014 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Presents Data on Multiple Anti-Cancer Stem Cell Programs at American Association for Cancer Research Annual Meeting

REDWOOD CITY, Calif. and SAN DIEGO, April 8, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells...
March 18, 2014 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals Announces Full Year and Fourth Quarter 2013 Financial Results

Year-End Cash and Cash Equivalents Balance of $316.2 Million Reflecting IPO and Celgene Multi-Product Co-Development Collaboration Names Sunil Patel Chief Financial Officer, SVP Corporate...
March 06, 2014 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed to Present Data on Anti-Cancer Stem Cell Candidates at the American Association of Cancer Research Meeting

REDWOOD CITY, Calif., March 6, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
February 28, 2014 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 28, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
February 20, 2014 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals Commences Third Phase 1b Clinical Trial for OMP-54F28 (Fzd8-Fc) With Carboplatin and Paclitaxel in Ovarian Cancer

REDWOOD CITY, Calif., Feb. 20, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
February 18, 2014 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals Initiates Second Phase 1b Clinical Trial for OMP-54F28 (Fzd8-Fc) With Sorafenib (Nexavar(R)) in Hepatocellular Cancer

REDWOOD CITY, Calif., Feb. 18, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...